Licensing & partnership
Qyuns licenses a second TL1A bispecific to Caldera, this time paired with IL-17
Qyuns Therapeutics granted Caldera Therapeutics exclusive global rights to a preclinical antibody that hits TL1A together with IL-17A and IL-17A/F, in a deal valued at up to $780 million. It is the second licence between the two companies, after their 2025 agreement on QX030N, an IL-23p19 by TL1A bispecific aimed at inflammatory bowel disease.
Written by Gosset from public sources. Source types: SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.